Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1365-2559.2011.03996.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic significance of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and monocyte-to-lymphocyte ratio in uterine carcinosarcoma.
Int J Clin Oncol
January 2025
Department of Gynecology and Obstetrics, Graduate School of Medicine and Faculty of Medicine, Kyoto University, 54 Kawahara-Cho, Shogoin, Sakyo-Ku, Kyoto, 606-8507, Japan.
Introduction: Uterine carcinosarcoma (UCS) and uterine sarcomas (US) are rare but aggressive cancer with poor prognoses. The prognostic value of systemic inflammatory response (SIR) indicators, including the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR), in predicting outcomes of UCS and US remains unclear. This study investigated the prognostic significance of SIR indicators for UCS and US.
View Article and Find Full Text PDFA Comprehensive Pan-Cancer Analysis Reveals GRB7 as a Potential Diagnostic and Prognostic Biomarker.
Cureus
December 2024
Genetics/Bioinformatics, Sidra Medicine, Ar-Rayyan, QAT.
Background And Aim: Growth factor receptor-bound protein 7 (GRB7) belongs to a group of adaptor proteins characterized by their conserved multidomain structure. These proteins are involved in cellular signaling pathways that regulate cell growth, proliferation, and differentiation. Alterations in GRB7 expression have been linked to multiple human cancers.
View Article and Find Full Text PDFTOURISM study (Treatment Outcomes in UteRIne SarcoMa): a 10-year retrospective evaluation of practice in the UK.
BMJ Open
December 2024
Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK.
Background: Although rare, uterine sarcomas account for a high proportion of uterine cancer mortality. Treatment options and robust trial data are limited.
Objectives: The TOURISM study (Treatment Outcomes in UteRIne SarcoMa) is a UK-wide study by the National Oncology Trainees Collaborative for Healthcare Research which aimed to characterise this patient cohort.
Case report: Carcinosarcoma of uterus in nulliparous women.
Front Oncol
December 2024
Gynecologic Oncology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Article Synopsis
- Uterine carcinosarcoma (UCS) is a rare cancer combining both carcinoma and sarcoma features, often resembling endometrial carcinoma, with a potential link to nulliparity (never having given birth) as a risk factor.
- A 55-year-old woman presented with postmenopausal vaginal bleeding and was diagnosed after surgery, revealing well-differentiated adenocarcinoma and osteosarcoma components, along with multiple positive immunohistochemical markers.
- Following a series of surgical interventions and treatments, including chemotherapy and radiotherapy, the patient demonstrated no signs of tumor recurrence and had a disease-free survival of seven months as of July 2024.
Explainable machine learning for predicting recurrence-free survival in endometrial carcinosarcoma patients.
Front Artif Intell
December 2024
Laboratorio di Biostatistica e Bioinformatica, Fisica Sanitaria, I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Objectives: Endometrial carcinosarcoma is a rare, aggressive high-grade endometrial cancer, accounting for about 5% of all uterine cancers and 15% of deaths from uterine cancers. The treatment can be complex, and the prognosis is poor. Its increasing incidence underscores the urgent requirement for personalized approaches in managing such challenging diseases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!